MagnetisMM-15

Elranatamab Post Trial Access: An Open-Label, Single-Arm Study For Participants with Multiple Myeloma Continuing From Pfizer-Sponsored Elranatamab Clinical Studies

What's the purpose of the trial?

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Trial status

Not yet accepting

Phase
Phase 4
Enrollment
72
Last Updated
2 months ago
Patient Screener

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Elranatamab is a B-Cell Maturation Antigen (BCMA) CD-3 bispecific antibody being tested in multiple myeloma

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Not yet accepting

Elranatamab

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.